Pharma&Biotech;
Navigate the Valley of Death
Reduce Attrition Rates and Improve Clinical Safety
The pharmaceutical industry is facing a number of challenges including escalating
R&D; costs, lower approval rates and more stringent regulatory scrutiny.
Lonza's new Developability Platform will help you navigate the transition from
Pre-clinical to Phase 1 clinical trials by reducing your costs, risk and overall
development time. Our Assessment Services consist of a suite of in silico tools
allowing you to identify your most promising candidate before entering clinical
trials.
For more information, contact us at:
Tel. +1 201 316 9200 North America
Tel. +41 61 316 8211 Europe & Asia
www.lonza.com/developability
©2013 Lonza Biologics, Inc.
Lonza's Developability Platform Includes:
– Manufacturability Assessment Service
Analysis of chemical degradation pathways and
post translational modifcations
– Safety Assessment Service
T-cell epitopes in target proteins
Benefts of Early Risk Assessment
–
–
–
–
–
Reduction in development costs and time
Acceleration of the lead candidate selection
Increase chance of a candidates success
Early process optimization
Confdence in manufacturing scale-up
www.lonza.com/developability